Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine

• DOI: 10.1016/j.bbrc.2006.12.111
• Publication Date: 2006-12-23T12:13:56Z
• Authors: Amosy E. M’Koma; David L. Blum; Jeremy L. Norris; Tatsuki Koyama; Dean Billheimer; Saundra Motley; Mayshan Ghiassi; Nika Ferdowsi; Indrani Bhowmick; Sam S. Chang; Jay H. Fowke; Richard M. Caprioli; Neil A. Bhowmick
• Keywords: Male; Prostatic Intraepithelial Neoplasia; Proteomics; 0303 health sciences; Prostatic Hyperplasia; Prostatic Neoplasms; Middle Aged; 6. Clean water; 3. Good health; 03 medical and health sciences; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Humans; Peptides; Precancerous Conditions; Aged

The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2% specificity and 67.4% sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6% specificity and 69.2% sensitivity. Comparing PCa and HGPIN resulted in 80.8% specificity and 81.0% sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.